Frontiers in oncology · 2026
Immune checkpoint inhibitor-related intestinal pseudo-obstruction and multisystem immune-related adverse events in a post-gastrectomy patient: a case report and literature review.
Клинический случайСтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Liu Zhening, Wang Chao, Shen Yulei, Shi Yanfen, Duan Jianghui, Dong Huijing, Xu Yangbo, Zheng Yumin, Cui Huijuan
Аннотация
BACKGROUND: Immune checkpoint inhibitors are increasingly recognized to be associated with multisystem immune-related adverse events. Cases presenting predominantly with intestinal pseudo-obstruction (IPO) are rare, prone to misdiagnosis, and may indicate broader immune-mediated toxicity.
CASE PRESENTATION: We report the case of a patient with gastric cancer who developed intestinal pseudo-obstruction and multisystem immune toxicity during postoperative adjuvant chemotherapy plus nivolumab. The patient's symptoms improved rapidly after glucocorticoid treatment.
CONCLUSION: Immune checkpoint inhibitor-related intestinal pseudo-obstruction (irIPO) should be recognized early and diagnosed on the basis of a comprehensive clinical assessment. Differential diagnosis, multidisciplinary collaboration, and active screening for additional organ involvement are essential. Early glucocorticoid treatment may improve clinical outcomes.
CASE PRESENTATION: We report the case of a patient with gastric cancer who developed intestinal pseudo-obstruction and multisystem immune toxicity during postoperative adjuvant chemotherapy plus nivolumab. The patient's symptoms improved rapidly after glucocorticoid treatment.
CONCLUSION: Immune checkpoint inhibitor-related intestinal pseudo-obstruction (irIPO) should be recognized early and diagnosed on the basis of a comprehensive clinical assessment. Differential diagnosis, multidisciplinary collaboration, and active screening for additional organ involvement are essential. Early glucocorticoid treatment may improve clinical outcomes.